Close Menu

NEW YORK – Chinese precision oncology platform company Genetron Holdings and its strategic partner CStone Pharmaceuticals said on Friday that they have launched a multi-center clinical trial in China for the joint development of a companion diagnostic test for avapritinib (Blueprint Medicines's Ayvakit).

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.